Abstract: The invention provides methods for the synthesis of oligosaccharides comprising an aminooxy group. The invention further provides oligosaccharides comprising an aminooxy group, methods for coupling oligosaccharides comprising an aminooxy group to glycoproteins, and oligosaccharide-protein conjugates. Also provided are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-protein conjugate.
Type:
Grant
Filed:
January 18, 2008
Date of Patent:
June 24, 2014
Assignee:
Genzyme Corporation
Inventors:
Yunxiang Zhu, Seng H. Cheng, Canwen Jiang, Luis Z. Avila
Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of apolipoprotein B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding apolipoprotein B. Methods of using these compounds for modulation of apolipoprotein B expression and for treatment of diseases associated with expression of apolipoprotein B are provided.
Abstract: A method of treating a glomerular disease selected from the group consisting of mesangial proliferative glomerulonephritis, collapsing glomerulopathy, proliferative lupus nephritis, crescentic glomerulonephritis and membranous nephropathy in a subject comprises administering to the subject an effective amount of a glucosylceramide synthase inhibitor.
Type:
Grant
Filed:
February 7, 2013
Date of Patent:
May 20, 2014
Assignee:
Genzyme Corporation
Inventors:
Oxana Ibraghimov-Beskrovnaya, Thomas Natoli
Abstract: The invention provides methods for reducing undesired immune responses, such as anti-drug antibody (ADA) responses and other T- and/or B-cell-mediated immune responses, in patients by using treatment with methotrexate.
Type:
Application
Filed:
May 3, 2012
Publication date:
May 15, 2014
Applicant:
GENZYME CORPORATION
Inventors:
Alexandra Joseph, Susan Richards, Melanie Ruzek, Richard Garman
Abstract: The disclosure provides methods for treating fatty liver disease and associated conditions by inhibiting the synthesis of glucosphingolipids, as exemplified by the use of glucosylceramide synthase substrate analogs.
Type:
Grant
Filed:
May 9, 2007
Date of Patent:
May 6, 2014
Assignee:
Genzyme Corporation
Inventors:
Hongmei Zhao, Nelson S. Yew, Seng H. Cheng, Canwen Jiang, Cynthia Marie Arbeeny
Abstract: The invention relates to dose escalation enzyme replacement therapy using acid sphingomyelinase (ASM) for the treatment of human subjects having acid sphingomyelinase deficiency (ASMD), and, in particular, patients with non-neurological manifestations of Niemann-Pick Disease (NPD), and in certain embodiments, NPD type B.
Type:
Grant
Filed:
November 16, 2012
Date of Patent:
April 29, 2014
Assignees:
Icahn School of Medicine at Mount Sinai, Genzyme Corporation
Inventors:
Edward H. Schuchman, Robert J. Desnick, Gerald F. Cox, Laura P. Andrews, James M. Murray
Abstract: This invention provides methods of measuring the viability of cultured cells by detecting one or more cell death-stable proteins or enzyme activities. Methods provided by the invention correlate viability to relative levels of enzyme activity in cell-containing and non-cell-containing fractions of a cell culture.
Abstract: Inhibitors of dihydroorotate dehydrogenase (DHODH) for the Plasmodium enzyme have been identified and characterized. The inhibitors have high specificity, submicromolar efficacy against cultured parasite strains, exhibit drug-like properties, and are not overtly cytotoxic.
Type:
Grant
Filed:
May 7, 2009
Date of Patent:
April 22, 2014
Assignees:
Genzyme Corporation, Massachusetts Institute of Technology, President and Fellows of Harvard College
Inventors:
Cecilia Bastos, Michael L. Booker, Cassandra A. Celatka, Jon C. Clardy, Joseph Cortese, Vishal P. Patel, Renato Skerlj, Roger C. Wiegand, Dyann F. Wirth
Abstract: A pharmaceutical composition comprising in admixture a hyaluronic acid related component (HARC) and a pharmaceutically effective amount of triamcinolone hexacetonide (TAH). The composition is stable in an accelerated shelf life test in which the composition is heated to 80° C. for 24 hours.
Type:
Grant
Filed:
August 23, 2012
Date of Patent:
March 25, 2014
Assignee:
Genzyme Corporation
Inventors:
Grace Chang, Elizabeth Voschin, Li-Ping Yu, Eugene Skrabut
Abstract: To gain a better understanding of breast tumor angiogenesis, breast endothelial cells (ECs) were isolated and evaluated for gene expression patterns. When transcripts from breast ECs derived from normal and malignant breast tissues were compared, genes that were specifically elevated in tumor-associated breast endothelium were revealed. These results confirm that neoplastic and normal endothelium in human breast are distinct at the molecular level, and have significant implications for the development of anti-angiogenic therapies in the future.
Type:
Application
Filed:
October 29, 2013
Publication date:
February 27, 2014
Applicants:
Genzyme Corporation, The Johns Hopkins University
Abstract: Dendrimers comprising N-acyl urea terminal moieties are described herein. The dendrimers can be used, for example, in the treatment of arthritis.
Type:
Grant
Filed:
June 19, 2008
Date of Patent:
February 25, 2014
Assignee:
Genzyme Corporation
Inventors:
Luis Z. Avila, Robert J. Miller, Lauren Elizabeth Young, Rajesh Vasant Kamath
Abstract: The invention relates to dose escalation enzyme replacement therapy using acid sphingomyelinase (ASM) for the treatment of human subjects having acid sphingomyelinase deficiency (ASMD), and, in particular, patients with non-neurological manifestations of Niemann-Pick Disease (NPD), and in certain embodiments, NPD type B.
Type:
Grant
Filed:
November 16, 2012
Date of Patent:
February 25, 2014
Assignees:
Icahn School of Medicine at Mount Sinai, Genzyme Corporation
Inventors:
Edward H. Schuchman, Robert J. Desnick, Gerald F. Cox, Laura P. Andrews, James M. Murray
Abstract: Disclosed is a polymer or physiologically acceptable salt thereof. The polymer comprises a polymerized multifunctional amine monomer. The amine monomer comprises at least two amine groups and at least two acyclic nitrogen atoms that are connected through a —CH2CH2— group, provided that the amine monomer is not ethylenediamine or diethylenetriamine. The disclosed polymers can be used to bind anions in subject in need of such treatment.
Type:
Application
Filed:
October 17, 2013
Publication date:
February 13, 2014
Applicant:
Genzyme Corporation
Inventors:
Chad C. Huval, Pradeep Dhal, S. Randall Holmes-Farley
Abstract: The disclosure relates to methods of treating an infant at risk of developing bronchopulmonary dysplasia, including premature infants, by administering a TGF-? antagonist during the perinatal period, including the prenatal period and/or the postnatal period. For administration during the prenatal period, the TGF-? antagonist can be administered either directly to the infant in utero, or indirectly by administration to the mother.
Type:
Grant
Filed:
October 3, 2007
Date of Patent:
February 4, 2014
Assignee:
Genzyme Corporation
Inventors:
James B. Streisand, Jesse D. Roberts, Jr.
Abstract: Novel mechanism-based inhibitors of S-adenosyl-L-methionine decarboxylase are provided. These compounds of formula (1) inhibit the life cycle of trypanosomes, and are useful to treat subjects infected with African trypanosomes. The invention includes pharmaceutical compositions and methods of using the compounds of formula (1).
Abstract: The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human CD52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a humanized immunoglobulin or immunoglobulin light chain or heavy chain, and to a method of preparing a humanized immunoglobulin. The humanized immunoglobulins can be used in therapeutic applications to treat, for example, autoimmune disease, cancer, non-Hodgkin's lymphoma, multiple sclerosis and chronic lymphocytic leukemia.
Type:
Grant
Filed:
May 13, 2010
Date of Patent:
December 31, 2013
Assignee:
Genzyme Corporation
Inventors:
Bruce L Roberts, Srinivas Shankara, William Harold Brondyk, William M Siders
Abstract: Novel uses for anti-thymocyte globulin (ATG, e.g., Thymoglobulin®) and related compositions are described. In one aspect, ATG and, optionally, TGF-? are used for in vitro generation of regulatory T cells, which are useful for cell therapy of immune-mediated conditions. In another aspect, ATG is directly administered to a subject at a low dose (e.g., less than 1 mg/kg per day) to treat an immune-mediated condition. The immune-mediated conditions include, for example, transplant rejection, graft-versus-host disease, and autoimmune diseases.
Type:
Application
Filed:
August 28, 2013
Publication date:
December 26, 2013
Applicants:
The Brigham and Women's Hospital, Inc., Genzyme Corporation
Inventors:
Nader Najafian, Mohamed H. Sayegh, Melanie Ruzek, Srinivas Shankara, John Williams, Johanne Kaplan, John M. McPherson
Abstract: Systems, methods, and articles of manufacture are provided for managing regulatory data pertaining to a healthcare product. For example, the system may include a network interface for receiving, from a client terminal, a request for regulatory data related to regulatory activity about a product as it pertains to a regulatory authority. The system also includes interconnected information stores for storing regulatory data associated with the product, where the information stores may include: contact records associated with respective contacts with the regulatory authority; commitment records associated with respective commitments made to the regulatory authority; and product information records associated with respective documents associated with the product. The system also includes a processing module for identifying, in response to the received request, each contact record, commitment record, product information record, and central files record associated with the product related to the received request.
Type:
Grant
Filed:
December 20, 2011
Date of Patent:
December 17, 2013
Assignee:
Genzyme Corporation
Inventors:
Alison Lawton, Rachel Carle, Monica Mehta, Mary Durham, Richard J. Granfield, James Earl Kiely, David J. Puig
Abstract: Disclosed herein is a method of treating a patient suffering a myocardial infarction, particularly an acute myocardial infarction, or of reducing an adverse consequence of a myocardial infarction in a patient comprising administering an antagonist of TGF-? to the patient during the acute stage of the myocardial infarction.
Type:
Application
Filed:
September 1, 2011
Publication date:
December 12, 2013
Applicant:
Genzyme Corporation
Inventors:
Geoffrey Y Akita, Richard Gregory, Scott Lonning, Amelia Kudel
Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of apolipoprotein B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding apolipoprotein B. Methods of using these compounds for modulation of apolipoprotein B expression and for treatment of diseases associated with expression of apolipoprotein B are provided.
Type:
Grant
Filed:
September 27, 2012
Date of Patent:
February 11, 2014
Assignee:
Genzyme Corporation
Inventors:
Rosanne M. Crooke, Mark J. Graham, Susan M. Freier